Cigna Challenges FTC’s Report on Pharmacy Benefit Managers, Alleging Unconstitutional Actions and Misleading Claims
Cigna, FTC, Pharmacy Benefit Managers (PBMs), Express Scripts, Unconstitutional Report, Misleading Claims, Drug Prices, Healthcare System
Ascendis Challenges BioMarin’s Dominance with Promising Achondroplasia Drug Data
Achondroplasia, Ascendis Pharma, BioMarin, TransCon CNP, VOXZOGO, Dwarfism Treatment
Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer
Patritumab deruxtecan, HER3-targeted ADC, Non-small cell lung cancer (NSCLC), Phase III trial, HERTHENA-Lung02, Daiichi Sankyo, Merck & Co.
HPV-Based Cervical Cancer Screening: Insights into Sample Preference and Cost-Effectiveness
HPV testing, Cervical cancer screening, Sample preference, Cost-effectiveness, Screening guidelines
Biopharma Leaders Navigate AI ‘Hype Cycle’: Bayer, Daiichi Sankyo, and argenx Share Insights on AI Implementation in Marketing
AI in biopharma marketing, Bayer, Daiichi Sankyo, argenx, AI implementation, biopharma industry, AI hype cycle
AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease
AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala
Novo Nordisk and NanoVation Collaborate on $600M Genetic Medicine Deal for Rare and Cardiometabolic Diseases
Novo Nordisk, NanoVation, genetic medicine, lipid nanoparticle technology, cardiometabolic diseases, rare diseases, RNA delivery, base-editing therapies
FDA Approves Keytruda for First-Line Treatment of Malignant Pleural Mesothelioma
Keytruda, FDA approval, malignant pleural mesothelioma, MPM, first-line treatment, chemotherapy, pembrolizumab
FDA Enhances Transparency in Drug Review Process with Revised Document Structure
FDA, drug review process, transparency, document structure, regulatory oversight
Capricor Secures $35M Deal for European Rights to DMD Therapy Ahead of FDA Application
Capricor Therapeutics, Duchenne muscular dystrophy (DMD), cell therapy, FDA application, European rights, $35M deal